The US Food and Drug Administration (FDA) has approved vutrisiran (Amvuttra, Alnylam Pharmaceuticals) for the treatment of polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in ...

Since 1995 I have had the interesting experience of working as a neurologist in a large state prison whose primary mission is to provide medical care to inmates. A large proportion of my practice ...

On November 5, 2025, argenx SE announced that Health Canada approved VYVGART SC (efgartigimod alfa injection) as a monotherapy for adults with active chronic inflammatory demyelinating polyneuropathy ...

Polyneuropathy is one of the most common complications in people with diabetes. First symptoms are often pins-and-needles sensations in the feet. Although polyneuropathy is present in about 30 percent ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) affects the peripheral nerves. Tests to diagnose this condition include nerve conduction studies, electromyography, and sometimes an MRI. CIDP ...

Credit: Getty Images. Eplontersen is an investigational ligand-conjugated antisense medicine designed to reduce the production of TTR protein to treat both hereditary and nonhereditary forms of ATTR.

To invoke non-disclosure, insurers must show the condition was active when the policy was bought and medically linked to the ...

A patient with transthyretin amyloidosis (ATTR) who received the investigational gene therapy nexiguran ziclumeran (nex-z) in ...

(MENAFN- GlobeNewsWire - Nasdaq) Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) is a rare autoimmune disorder targeting the peripheral nervous system, causing muscle weakness and sensory ...

Susannah Sample shares canine research which could aid in understanding human diseases. Susannah Sample, Assistant Scientist at the School of Veterinary Medicine at UW-Madison, discusses the results ...

Citi raised the firm’s price target on Argenx (ARGX) to $1,124 from $1,041 and keeps a Buy rating on the shares. The firm left a meeting with ...